The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern
Rana Abdelnabi, Caroline S Foo, Dirk Jochmans, Laura Vangeel, Steven De Jonghe, Patrick Augustijns, Raf Mols, Birgit Weynand, Thanaporn Wattanakul, Richard M Hoglund, Joel Tarning, Charles E Mowbray, Peter Sjö, Fanny Escudié, Ivan Scandale, Eric Chatelain, Johan Neyts
doi:10.1101/2021.11.04.467077
There is an urgent need for potent and selective antivirals against SARS-CoV-2. Pfizer developed PF-07321332 (PF-332), a potent inhibitor of the viral main protease (Mpro, 3CLpro) that can be dosed orally and that is in clinical development. We here report that PF-332 exerts equipotent in vitro activity against the four SARS-CoV-2 variants of concerns (VoC) and that it can completely arrest replication of the alpha variant in primary human airway epithelial cells grown at the air-liquid interface. Treatment of Syrian Golden hamsters with PF-332 (250 mg/kg, twice daily) completely protected the animals against intranasal infection with the beta (B.1.351) and delta (B.1.617.2) SARS-CoV-2 variants. Moreover, treatment of SARS-CoV-2 (B.1.617.2) infected animals with PF-332 completely prevented transmission to untreated co-housed sentinels.
Ethics Housing conditions and experimental procedures were done with the approval and under the guidelines of the ethics committee of animal experimentation of KU Leuven (license P065-2020).
Conflict of interest
None to declare
Author
References
Abdelnabi, Comparing infectivity and virulence of emerging SARS-CoV-2 variants in Syrian hamsters, EBioMedicine
Abdelnabi, Molnupiravir Inhibits Replication of the Emerging SARS-CoV-2 Variants of Concern in a Hamster Infection Model, J. Infect. Dis
Abdelnabi, The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model, EBioMedicine
Boras, Discovery of a Novel Inhibitor of Coronavirus 3CL Protease for the Potential Treatment of COVID-19, bioRxiv,
doi:10.1101/2020.09.12.293498
Boudewijns, STAT2 signaling restricts viral dissemination but drives severe pneumonia in SARS-CoV-2 infected hamsters, Nat. Commun
Chen, Liu, Guo, Emerging coronaviruses: Genome structure, replication, and pathogenesis, Journal of Medical Virology
Do, A robust SARS-CoV-2 replication model in primary human epithelial cells at the air liquid interface to assess antiviral agents, Antiviral Res
Fan, The substrate specificity of SARS coronavirus 3C-like proteinase, Biochem. Biophys. Res. Commun
Ivens, Development of a homogeneous screening assay for automated detection of antiviral agents active against severe acute respiratory syndrome-associated coronavirus, J. Virol. Methods
Jin, Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors, Nature
Jochmans, Leyssen, Neyts, A novel method for high-throughput screening to quantify antiviral activity against viruses that induce limited CPE, J. Virol. Methods
Kabinger, Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis, Nat. Struct. Mol. Biol
Kaptein, Favipiravir at high doses has potent antiviral activity in SARS-CoV-2−infected hamsters, whereas hydroxychloroquine lacks activity, Proc. Natl. Acad. Sci. U. S. A
Keizer, Van Benten, Beijnen, Schellens, Huitema, Piraña and PCluster: A modeling environment and cluster infrastructure for NONMEM, Comput. Methods Programs Biomed
Kokic, Mechanism of SARS-CoV-2 polymerase stalling by remdesivir, Nat. Commun
Lindbom, Ribbing, Jonsson, Perl-speaks-NONMEM (PsN) -A Perl module for NONMEM related programming, Comput. Methods Programs Biomed
Pillaiyar, Manickam, Namasivayam, Hayashi, Jung, An overview of severe acute respiratory syndrome-coronavirus (SARS-CoV) 3CL protease inhibitors: Peptidomimetics and small molecule chemotherapy, Journal of Medicinal Chemistry
Schäfer, Therapeutic efficacy of an oral nucleoside analog of remdesivir against SARS-CoV-2 pathogenesis in mice, bioRxiv : the preprint server for biology,
doi:10.1101/2021.09.13.460111
Ullrich, Nitsche, The SARS-CoV-2 main protease as drug target, Bioorganic and Medicinal Chemistry Letters
{ 'institution': [{'name': 'bioRxiv'}],
'indexed': {'date-parts': [[2024, 3, 2]], 'date-time': '2024-03-02T00:24:36Z', 'timestamp': 1709339076428},
'posted': {'date-parts': [[2021, 11, 5]]},
'group-title': 'Microbiology',
'reference-count': 21,
'publisher': 'Cold Spring Harbor Laboratory',
'content-domain': {'domain': [], 'crossmark-restriction': False},
'accepted': {'date-parts': [[2021, 11, 5]]},
'abstract': '<jats:title>Abstract</jats:title><jats:p>There is an urgent need for potent and selective '
'antivirals against SARS-CoV-2. Pfizer developed PF-07321332 (PF-332), a potent inhibitor of '
'the viral main protease (Mpro, 3CLpro) that can be dosed orally and that is in clinical '
'development. We here report that PF-332 exerts equipotent <jats:italic>in vitro</jats:italic> '
'activity against the four SARS-CoV-2 variants of concerns (VoC) and that it can completely '
'arrest replication of the alpha variant in primary human airway epithelial cells grown at the '
'air-liquid interface. Treatment of Syrian Golden hamsters with PF-332 (250 mg/kg, twice '
'daily) completely protected the animals against intranasal infection with the beta (B.1.351) '
'and delta (B.1.617.2) SARS-CoV-2 variants. Moreover, treatment of SARS-CoV-2 (B.1.617.2) '
'infected animals with PF-332 completely prevented transmission to untreated co-housed '
'sentinels.</jats:p>',
'DOI': '10.1101/2021.11.04.467077',
'type': 'posted-content',
'created': {'date-parts': [[2021, 11, 5]], 'date-time': '2021-11-05T22:15:12Z', 'timestamp': 1636150512000},
'source': 'Crossref',
'is-referenced-by-count': 6,
'title': 'The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with '
'SARS-CoV-2 variants of concern',
'prefix': '10.1101',
'author': [ {'given': 'Rana', 'family': 'Abdelnabi', 'sequence': 'first', 'affiliation': []},
{'given': 'Caroline S.', 'family': 'Foo', 'sequence': 'additional', 'affiliation': []},
{ 'ORCID': 'http://orcid.org/0000-0002-9265-6028',
'authenticated-orcid': False,
'given': 'Dirk',
'family': 'Jochmans',
'sequence': 'additional',
'affiliation': []},
{'given': 'Laura', 'family': 'Vangeel', 'sequence': 'additional', 'affiliation': []},
{'given': 'Steven', 'family': 'De Jonghe', 'sequence': 'additional', 'affiliation': []},
{'given': 'Patrick', 'family': 'Augustijns', 'sequence': 'additional', 'affiliation': []},
{'given': 'Raf', 'family': 'Mols', 'sequence': 'additional', 'affiliation': []},
{'given': 'Birgit', 'family': 'Weynand', 'sequence': 'additional', 'affiliation': []},
{'given': 'Thanaporn', 'family': 'Wattanakul', 'sequence': 'additional', 'affiliation': []},
{'given': 'Richard M.', 'family': 'Hoglund', 'sequence': 'additional', 'affiliation': []},
{'given': 'Joel', 'family': 'Tarning', 'sequence': 'additional', 'affiliation': []},
{'given': 'Charles E.', 'family': 'Mowbray', 'sequence': 'additional', 'affiliation': []},
{'given': 'Peter', 'family': 'Sjö', 'sequence': 'additional', 'affiliation': []},
{'given': 'Fanny', 'family': 'Escudié', 'sequence': 'additional', 'affiliation': []},
{'given': 'Ivan', 'family': 'Scandale', 'sequence': 'additional', 'affiliation': []},
{'given': 'Eric', 'family': 'Chatelain', 'sequence': 'additional', 'affiliation': []},
{'given': 'Johan', 'family': 'Neyts', 'sequence': 'additional', 'affiliation': []}],
'member': '246',
'reference': [ { 'key': '2021110905200473000_2021.11.04.467077v1.1',
'doi-asserted-by': 'publisher',
'DOI': '10.1002/jmv.25681'},
{ 'key': '2021110905200473000_2021.11.04.467077v1.2',
'doi-asserted-by': 'crossref',
'first-page': '289',
'DOI': '10.1038/s41586-020-2223-y',
'article-title': 'Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors',
'volume': '582',
'year': '2020',
'journal-title': 'Nature'},
{ 'key': '2021110905200473000_2021.11.04.467077v1.3',
'doi-asserted-by': 'publisher',
'DOI': '10.1021/acs.jmedchem.5b01461'},
{ 'key': '2021110905200473000_2021.11.04.467077v1.4',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/j.bbrc.2005.02.061'},
{ 'key': '2021110905200473000_2021.11.04.467077v1.5',
'doi-asserted-by': 'crossref',
'unstructured': 'Ullrich, S. & Nitsche, C. The SARS-CoV-2 main protease as drug target. '
'Bioorganic and Medicinal Chemistry Letters 30, (2020).',
'DOI': '10.1016/j.bmcl.2020.127377'},
{ 'key': '2021110905200473000_2021.11.04.467077v1.6',
'doi-asserted-by': 'publisher',
'DOI': '10.1101/2020.09.12.293498'},
{ 'key': '2021110905200473000_2021.11.04.467077v1.7',
'doi-asserted-by': 'publisher',
'DOI': '10.1126/science.abl4784'},
{ 'key': '2021110905200473000_2021.11.04.467077v1.8',
'doi-asserted-by': 'crossref',
'unstructured': 'Do, T. N. D. et al. A robust SARS-CoV-2 replication model in primary '
'human epithelial cells at the air liquid interface to assess antiviral '
'agents. Antiviral Res. 192, (2021).',
'DOI': '10.1016/j.antiviral.2021.105122'},
{ 'key': '2021110905200473000_2021.11.04.467077v1.9',
'first-page': '6',
'volume': '3',
'author': 'Food and Drug Administration (FDA). Coronavirus (COVID-19) Update: FDA Issues '
'Emergency Use Authorization for Potential COVID-19 Treatment',
'year': '2020',
'journal-title': 'Press Announcements'},
{ 'key': '2021110905200473000_2021.11.04.467077v1.10',
'doi-asserted-by': 'crossref',
'unstructured': 'Kokic, G. et al. Mechanism of SARS-CoV-2 polymerase stalling by '
'remdesivir. Nat. Commun. 12, (2021).',
'DOI': '10.1038/s41467-020-20542-0'},
{ 'key': '2021110905200473000_2021.11.04.467077v1.11',
'doi-asserted-by': 'publisher',
'DOI': '10.1101/2021.09.13.460111'},
{ 'key': '2021110905200473000_2021.11.04.467077v1.12',
'doi-asserted-by': 'publisher',
'DOI': '10.1038/s41594-021-00651-0'},
{ 'key': '2021110905200473000_2021.11.04.467077v1.13',
'doi-asserted-by': 'crossref',
'unstructured': 'Abdelnabi, R. et al. The combined treatment of Molnupiravir and '
'Favipiravir results in a potentiation of antiviral efficacy in a '
'SARS-CoV-2 hamster infection model. EBioMedicine 72, (2021).',
'DOI': '10.1016/j.ebiom.2021.103595'},
{ 'key': '2021110905200473000_2021.11.04.467077v1.14',
'doi-asserted-by': 'crossref',
'first-page': '749',
'DOI': '10.1093/infdis/jiab361',
'article-title': 'Molnupiravir Inhibits Replication of the Emerging SARS-CoV-2 Variants '
'of Concern in a Hamster Infection Model',
'volume': '224',
'year': '2021',
'journal-title': 'J. Infect. Dis'},
{ 'key': '2021110905200473000_2021.11.04.467077v1.15',
'doi-asserted-by': 'publisher',
'DOI': '10.1073/pnas.2014441117'},
{ 'key': '2021110905200473000_2021.11.04.467077v1.16',
'doi-asserted-by': 'crossref',
'first-page': '103403',
'DOI': '10.1016/j.ebiom.2021.103403',
'article-title': 'Comparing infectivity and virulence of emerging SARS-CoV-2 variants in '
'Syrian hamsters',
'volume': '68',
'year': '2021',
'journal-title': 'EBioMedicine'},
{ 'key': '2021110905200473000_2021.11.04.467077v1.17',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/j.jviromet.2005.05.010'},
{ 'key': '2021110905200473000_2021.11.04.467077v1.18',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/j.jviromet.2012.04.011'},
{ 'key': '2021110905200473000_2021.11.04.467077v1.19',
'doi-asserted-by': 'publisher',
'DOI': '10.1038/s41467-020-19684-y'},
{ 'key': '2021110905200473000_2021.11.04.467077v1.20',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/j.cmpb.2003.11.003'},
{ 'key': '2021110905200473000_2021.11.04.467077v1.21',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/j.cmpb.2010.04.018'}],
'container-title': [],
'original-title': [],
'link': [ { 'URL': 'https://syndication.highwire.org/content/doi/10.1101/2021.11.04.467077',
'content-type': 'unspecified',
'content-version': 'vor',
'intended-application': 'similarity-checking'}],
'deposited': { 'date-parts': [[2022, 5, 25]],
'date-time': '2022-05-25T19:50:24Z',
'timestamp': 1653508224000},
'score': 1,
'resource': {'primary': {'URL': 'http://biorxiv.org/lookup/doi/10.1101/2021.11.04.467077'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2021, 11, 5]]},
'references-count': 21,
'URL': 'http://dx.doi.org/10.1101/2021.11.04.467077',
'relation': { 'is-preprint-of': [ { 'id-type': 'doi',
'id': '10.1038/s41467-022-28354-0',
'asserted-by': 'subject'}]},
'subject': [],
'published': {'date-parts': [[2021, 11, 5]]},
'subtype': 'preprint'}